CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

CareDx The Transplant Company Surpasses 80,000 Patient Milestone https://finance.yahoo.com/news/caredx-transplant-company-surpasses-80-120000159.html Over 80,000 Heart, Kidney, and Lung Organ Transplant Recipients Have Used AlloSure or AlloMap in their Post-Transplant Care

CareDx Acquires MedActionPlan to Directly Support Patients with Better Adherence https://finance.yahoo.com/news/caredx-acquires-medactionplan-directly-support-120000499.html MedActionPlan adds a robust medication adherence platform to the CareDx digital suite, currently used in more than 100 hospitals and health systems

University of Alabama Integrates CareDx’s TxAccess for Connection to Over 500 Community Practices https://www.globenewswire.com/news-release/2021/11/04/2327294/31386/en/University-of-Alabama-Integrates-CareDx-s-TxAccess-for-Connection-to-Over-500-Community-Practices.html TxAccess Supports and Accelerates Patients onto the Transplant Waitlist

CareDx drops despite Q3 beat amid concerns over regulatory investigations https://seekingalpha.com/news/3760894-caredx-drops-despite-q3-beat-amid-concerns-over-regulatory-investigations

CareDx Reports Third Quarter 2021 Results; Increases Full Year Revenue Guidance https://www.globenewswire.com/news-release/2021/10/28/2323150/31386/en/CareDx-Reports-Third-Quarter-2021-Results-Increases-Full-Year-Revenue-Guidance.html ... Recent Highlights: • Achieved record revenue of $75.6 million for the three months ended September 30, 2021, increasing 42% year-over-year • Grew testing services volume 86% year-over-year, with approximately 40,000 AlloSure and AlloMap patient results provided in the quarter - highlighted by an approximately 90% attach rate for HeartCare • Announced publication of KidneyCare validation study in Kidney360 – Multicenter study validating AlloMap and demonstrating the complementary value with AlloSure for detecting rejection • Received first commercial AlloSure Lung coverage, followed by commercial launch of AlloSure Lung, the first dd-cfDNA test available for lung transplant patients, in October ... 2021 Guidance For the full year 2021, CareDx now expects revenue to be in the range of $290 million to $293 million (previously $280 million to $290 million).

CareDx’s AlloSure Demonstrates Better Accuracy Than Current Standards of Care in Independent Kidney Transplant Study https://www.globenewswire.com/news-release/2021/10/21/2318166/31386/en/CareDx-s-AlloSure-Demonstrates-Better-Accuracy-Than-Current-Standards-of-Care-in-Independent-Kidney-Transplant-Study.html Landmark Longitudinal Study in Over 1,000 Transplant Patients Confirms AlloSure More Accurately Measures Organ Health

CareDx and Eledon Pharmaceuticals Announce Collaborative Research Agreement https://finance.yahoo.com/news/caredx-eledon-pharmaceuticals-announce-collaborative-110000256.html Eledon to use AlloSure to help assess the efficacy of AT-1501 in the prevention of rejection in Eledon’s upcoming renal transplantation trials

CareDx to appeal after Court rules in favor of Natera in patent battle https://newsfilter.io/a/268d6a0bdaadda6774a250967107e9cc • Natera (NASDAQ:NTRA) has suffered a setback in a patent infringement case against CareDx (NASDAQ:CDNA). A Delaware Federal District Court has ruled that all three patents CareDx (CDNA) has asserted against Natera (NTRA) were invalid. • Natera (NTRA) expects the judgment over its '658 and '724 patents to be upheld on appeal, the company said. • Meanwhile, issuing a statement, CareDx (CDNA) said it “respectfully disagrees with the court’s ruling and intends to appeal.” • “While the trial court’s patent ineligibility finding for these three patents has no impact on our ability to continue providing AlloSure, we continue to believe Natera and Eurofins Viracor are infringing these patents,” it added. • In 2019, Stanford and CareDx, licensee of the patents, filed an infringement lawsuit against Natera and Eurofins Viracor. • The patents in question relate to the methods for non-invasive monitoring of organ transplant rejection through cell-free DNA analysis used in the company’s AlloSure diagnostic solution.

https://www.globenewswire.com/news-release/2021/09/27/2303452/31386/en/CareDx-Presents-Latest-Data-on-AlloSeq-Portfolio-at-ASHI-2021.html

CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance https://www.globenewswire.com/news-release/2021/07/29/2271713/31386/en/CareDx-Reports-77-Revenue-Growth-for-Second-Quarter-of-2021-and-Increases-Full-Year-Revenue-Guidance.html ... Recent Highlights: • Achieved total revenue of $74.2 million for the three months ended June 30, 2021, increasing 77% year-over-year • Total AlloSure and AlloMap patient results provided in the quarter were approximately 37,400, which includes approximately 6,600 AlloSure Heart patient results • As of June 30, 2021, over 65 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol. In addition, TX Connect now manages more than 29,000 transplant referrals to over 50 transplant centers from more than 800 dialysis centers and community nephrology practices • Presented positive data from first 1,000 patients from KOAR Study demonstrating higher 1-year graft survival and reduction in biopsies through ARTS surveillance ...

CareDx Launches ACROBAT Study to Potentially Change Care Paradigm for Stem Cell Transplant Patients https://www.globenewswire.com/news-release/2021/07/26/2268442/31386/en/CareDx-Launches-ACROBAT-Study-to-Potentially-Change-Care-Paradigm-for-Stem-Cell-Transplant-Patients.html ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ...

CareDx To Acquire Transplant Hero Medication Management Application https://www.globenewswire.com/news-release/2021/06/08/2243452/31386/en/CareDx-To-Acquire-Transplant-Hero-Medication-Management-Application.html Acquisition adds to growing digital portfolio for patients and transplant centers

CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS Surveillance https://www.globenewswire.com/news-release/2021/06/07/2242580/31386/en/CareDx-Presents-Landmark-KOAR-1000-Data-Demonstrating-Higher-1-Year-Graft-Survival-and-Reduction-in-Biopsies-through-ARTS-Surveillance.html KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled

CareDx Advances Artificial Intelligence in Transplantation Partnership with OrganX to develop decision support systems https://www.globenewswire.com/news-release/2021/06/03/2241712/31386/en/CareDx-Advances-Artificial-Intelligence-in-Transplantation.html CareDx Presents Groundbreaking AlloSure® Data at the 2021 American Transplant Congress https://markets.businessinsider.com/news/stocks/caredx-presents-groundbreaking-allosure-data-at-the-2021-american-transplant-congress-1030494698

CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare https://www.globenewswire.com/news-release/2021/06/01/2239480/0/en/CareDx-Starts-Enrollment-in-MAPLE-a-Multi-modal-Multi-center-Prospective-Study-of-LiverCare.html Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients

CareDx Announces Strategic Minority Investment in Miromatrix https://www.globenewswire.com/news-release/2021/05/28/2238527/0/en/CareDx-Announces-Strategic-Minority-Investment-in-Miromatrix.html Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs